5 Best Biotech Stocks with Highest Upside Potential

3. Structure Therapeutics Inc. (NASDAQ:GPCR)

Structure Therapeutics Inc. (NASDAQ:GPCR) is one of the 10 best biotech stocks with highest upside potential.

As of April 24 closing, the stock carries a strongly bullish consensus sentiment, receiving Buy ratings from all 14 analysts. Based on a 1-year median target price of $107.77, it currently offers an upside potential of almost 138%.

Back on March 16, Structure Therapeutics Inc. (NASDAQ:GPCR) released encouraging results of the Phase 2 ACCESS II study conducted on its investigational product called aleniglipron. It is an oral GLP-1 receptor agonist for use against obesity. It achieved 16.3% weight reduction when taken at 180 mg and 16% weight loss when taken at a higher dose of 240 mg at 44 weeks.

The open-label extension trial reported further weight reduction up to 16.2% for the 120 mg dose after 56 weeks without any sign of weight loss plateauing. It should be mentioned that the lower 2.5 mg starting dose significantly enhanced the tolerability of the drug by lowering the rate of adverse events associated with drug discontinuations to only 2 to 3.4%.

The end-of-phase 2 meeting with the FDA is scheduled to take place during the second quarter of 2026, while phase 3 is still set to start in the second half of 2026. According to Chief Executive Raymond Stevens, the data shows that the company’s drug is significantly different from others because it achieves the highest amount of weight loss in an oral GLP-1 drug.

Structure Therapeutics Inc. (NASDAQ:GPCR) is involved in the development and marketing of novel oral small molecule therapies for the treatment of several chronic diseases with unmet medical needs. The company is currently working on several drug candidates, which include GSBR-1290, ACCG-2671, ACCG-3535, LTSE-2578, and ANPA-0073. Additionally, it also develops programs like the GCG and GIPR programs.